We are live on ! Find out more
CTIC

CTI BioPharma Corp. (DE) Common Stock
CTIC

Delisted

CTIC was delisted on the 23rd of June, 2023.

Back to rankings

62 hedge funds and large institutions have $141M invested in CTI BioPharma Corp. (DE) Common Stock in 2020 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

480% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 5

284% more call options, than puts

Call options by funds: $748K | Put options by funds: $195K

65% more capital invested

Capital invested by funds: $85.1M → $141M (+$55.6M)

63% more funds holding

Funds holding: 38 → 62 (+24)

33% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 9

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
62
Holders Change
+24
Holders Change %
+63.16%
% of All Funds
1.09%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
29
Increased
12
Reduced
9
Closed
5
Calls
$748K
Puts
$195K
Net Calls
+$553K
Net Calls Change
+$134K

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$8.36M
2
GTC
Ghost Tree Capital
New York
+$2.49M
3
Millennium Management
Millennium Management
New York
+$1.27M
4
Morgan Stanley
Morgan Stanley
New York
+$1.25M
5
RPAM
Rhenman & Partners Asset Management
Sweden
+$998K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$5.7M
2
CC
Caxton Corporation
New Jersey
-$1.88M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.32M
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$367K
5
Group One Trading
Group One Trading
Illinois
-$109K

CTIC Hedge Fund Activity: Q4 2020 in Review

62 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q4 2020, worth a combined $141M — up 65% from $85.1M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new CTIC positions and 5 closed out — a net gain of 24 holders — while 12 added to existing stakes and 9 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $8.36M. The largest seller was Stonepine Capital Management, cutting an estimated $5.7M.

  • 62 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q4 2020, up from 38 in Q3 2020.
  • Funds reported $141M of CTI BioPharma Corp. (DE) Common Stock stock for Q4 2020, up 65% quarter-over-quarter.
  • 29 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q4 2020 and 5 closed out, a net change of +24 holders.
  • The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q4 2020 was Consonance Capital Management, an estimated $8.36M added.
  • The largest CTI BioPharma Corp. (DE) Common Stock seller in Q4 2020 was Stonepine Capital Management, an estimated $5.7M sold.

Based on aggregated 13F filings for Q4 2020.